Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? (Q40977680)

25 September 2017

Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? (English)

1 reference

25 September 2017

1 reference

Gunda Millonig

1

1 reference

25 September 2017

Michaela Kern

2

1 reference

25 September 2017

Othmar Ludwiczek

3

1 reference

25 September 2017

Karin Nachbaur

4

1 reference

25 September 2017

Wolfgang Vogel

5

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

World Journal of Gastroenterology

25 September 2017

1 reference

25 September 2017

12

1 reference

25 September 2017

6

1 reference

25 September 2017

974-976

1 reference

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Infliximab for the treatment of fistulas in patients with Crohn's disease

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor

4 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4066168

Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis

4 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16521231

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16521231

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3748/WJG.V12.I6.974

1 reference

25 September 2017

1 reference

25 September 2017

1 reference